Navigation Links
Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations
Date:8/27/2009

s were over 40, and either former or current smokers with a smoking history of at least 20 pack-years. The patients had symptoms of chronic cough and sputum, their post-bronchodilator FEV(1) was less than or equal to 50percent of the predicted value and they had at least one documented moderate to severe exacerbation in the previous year. Approximately 50percent of the patients were concomitantly using long acting beta agonists.

Patients were permitted to use short-acting bronchodilators to relieve their symptoms as needed.

Compared with placebo, roflumilast significantly reduced the rate of exacerbations and improved lung function in treated patients. The rate of moderate to severe exacerbations in the study period (pooled data) was 1.14 per year in the patients treated with roflumilast compared with 1.37 per year, in the placebo group. This represents an improvement of 17 percent (RR 0.83; CI 0.75-0.92, p<0.001).

The pooled data for lung function using the pre-bronchodilator FEV(1) measurement (forced expiratory volume in one second) showed an average increase of 48mL (p<0.001) in roflumilast treated patients compared with the placebo group. The improvement in post-bronchodilator FEV(1) was 55mL (p<0.001) with roflumilast.

The differences found in exacerbation rates and lung function were similar irrespective of whether roflumilast was used with or without a long-acting beta-agonist.

Using another measurement, FVC (forced vital capacity, the lung capacity measured when the patient is exhaling for as hard and as long as possible) roflumilast patients also scored higher with an average increased FVC of 98 mL (p<0.001) compared with the placebo group. These patients had not used a bronchodilator prior to testing. The improvement in post-bronchodilator FVC was 101 mL (p<0.001).

Roflumilast was well tolerated by most patients. Slightly more
'/>"/>

SOURCE Nycomed
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
3. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
4. PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
5. Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. School of Dentistry Studies Link Between Oral Health and Memory
8. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
9. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pipeline Insight 2014" report to their offering. ... eradicate the prevalence of cancer have achieved limited success ... specificity, safety and large number of side effects, which ... It has been discovered that peptides can be used ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... , June 26, 2010 Amylin Pharmaceuticals, ... Company (NYSE: LLY ) today announced results ... with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) ... the pancreas that produce insulin.) Three years of BYETTA ...
... ORLANDO, Fla. , June 26, 2010 ... Lilly and Company (NYSE: LLY ) and ... of an analysis of pooled safety data from three ... BYDUREON™ (exenatide extended-release for injectable suspension), dosed once weekly, ...
Cached Medicine Technology:Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 2Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 3Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 4Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 5Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 6Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 7Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 8BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 2BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 3BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 4BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 5BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 6BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 7BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 8BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 9
(Date:9/1/2014)... The National Association of Hispanic Nurses ( ... DNP, MPH, RN, and Adriana Perez, PhD, Rn, ANP-BC, ... Nursing. They will be inducted with Immediate Past President ... we reported last May. , Our three members will ... American Academy of Nursing Policy Conference in Washington, DC. ...
(Date:9/1/2014)... 2014 Bioinformatics refers to an ... biological and genetic data. A major part of ... software tools to generate and process useful biological ... biological computation. While bioinformatics simply makes use of ... its related concepts, biological computation refers to the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web hosting ... Top10BestSEOHosting.com is here to announce that JustHost, Bluehost ... in 2014. , JustHost ( http://www.justhost.com/track/seohosts ) provides ... hosting plan. The company’s approach to hosting is ... accessible and powerful enough for anyone to use. ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... Dec. 19 House Republican Whip,Roy Blunt (Mo.) issued ... funding under the State Children,s Health Insurance,Program (SCHIP) through ... days of the first session of the 110th,Congress, the ... for months - a proposal to extend the current ...
... IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced today ... Conference. Jonathan W. Ayers, Chairman,President and CEO, is scheduled ... 7, 2008 at 8:00 a.m. (PT), at the Westin ... live audio webcast of,the presentation through a link on ...
... Stronger National,Measures, Urges America,s Health Insurance Plan Proposal ... The National Patient,Advocate Foundation (NPAF) -- a national, ... to health care through state and,federal public policy ... today in its Individual Market Guarantee Access,Proposal that ...
... introduce NutreStore(TM) in spring 2008, TORRANCE, ... a,Torrance, California based pharmaceutical company, announced today ... agreement with Cato BioVentures of,Research Triangle Park, ... brand L-Glutamine. Under this agreement, Emmaus will,commercialize ...
... happiness and sadness. Although lost opportunities and mistaken expectations ... experiences may impact personality development and overall happiness. A ... the University of Missouri, indicates that individuals who take ... more likely to mature and achieve a potentially more ...
... in tumor-suppressing gene could point to lymph node involvement, ... Supposedly "innocent" cells in the area surrounding cancerous tumors ... can predict whether or not the cancer spreads to ... of alterations in the tumor-suppressing p53 gene in the ...
Cached Medicine News:Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 2Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 3Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 2Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 3Health News:What's the rush? Taking time to acknowledge loss is not that bad 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 3
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Medicine Products: